|Bid||13.16 x 900|
|Ask||13.90 x 1000|
|Day's range||13.30 - 13.47|
|52-week range||11.25 - 17.98|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||20.83|
Leverkusen, Germany, June 12, 2018-- Biofrontera AG, an international biopharmaceutical company, today announced that it has filed a complaint in the United States District Court for the Southern District ...
Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2018 and provided an update on recent operational and clinical developments. “We entered 2018 with a strong presence in the U.S. achieving record revenue increase and successfully completing an initial public offering on the Nasdaq Capital Market. Combined with a preemptive rights offering in Germany, Biofrontera raised €21.6 million in net proceeds that will support our expansion opportunities.
Leverkusen, Germany, April 30, 2018--. Biofrontera AG, an international biopharmaceutical company, today reported its consolidated financial results for the full year ended December 31, 2017 and provided ...
Leverkusen, Germany, April 12, 2018-- Biofrontera AG, the specialist for the treatment of sun-induced skin cancer, today announced preliminary unaudited revenue for the first quarter of fiscal year 2018.. ...